Literature DB >> 21856768

Significant biological role of sp1 transactivation in multiple myeloma.

Mariateresa Fulciniti1, Samir Amin, Puru Nanjappa, Scott Rodig, Rao Prabhala, Cheng Li, Stephane Minvielle, Yu-Tzu Tai, Pierfrancesco Tassone, Herve Avet-Loiseau, Teru Hideshima, Kenneth C Anderson, Nikhil C Munshi.   

Abstract

PURPOSE: The transcription factor specificity protein 1 (Sp1) controls number of cellular processes by regulating the expression of critical cell cycle, differentiation, and apoptosis-related genes containing proximal GC/GT-rich promoter elements. We here provide experimental and clinical evidence that Sp1 plays an important regulatory role in multiple myeloma (MM) cell growth and survival. EXPERIMENTAL
DESIGN: We have investigated the functional Sp1 activity in MM cells using a plasmid with Firefly luciferase reporter gene driven by Sp1-responsive promoter. We have also used both siRNA- and short hairpin RNA-mediated Sp1 knockdown to investigate the growth and survival effects of Sp1 on MM cells and further investigated the anti-MM activity of terameprocol (TMP), a small molecule that specifically competes with Sp1-DNA binding in vitro and in vivo.
RESULTS: We have confirmed high Sp1 activity in MM cells that is further induced by adhesion to bone marrow stromal cells (BMSC). Sp1 knockdown decreases MM cell proliferation and induces apoptosis. Sp1-DNA binding inhibition by TMP inhibits MM cell growth both in vitro and in vivo, inducing caspase-9-dependent apoptosis and overcoming the protective effects of BMSCs.
CONCLUSIONS: Our results show Sp1 as an important transcription factor in myeloma that can be therapeutically targeted for clinical application by TMP. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856768      PMCID: PMC4318245          DOI: 10.1158/1078-0432.CCR-11-1036

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities.

Authors:  H Ishibashi; K Nakagawa; M Onimaru; E J Castellanous; Y Kaneda; Y Nakashima; K Shirasuna; K Sueishi
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

2.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.

Authors:  F Li; D C Altieri
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

3.  Induction of endoplasmic reticulum-induced stress genes in Panc-1 pancreatic cancer cells is dependent on Sp proteins.

Authors:  Maen Abdelrahim; Shengxi Liu; Stephen Safe
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

4.  Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression.

Authors:  Masashi Kanai; Daoyan Wei; Qiang Li; Zhiliang Jia; Jaffer Ajani; Xiangdong Le; James Yao; Keping Xie
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

5.  Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans.

Authors:  J N Gnabre; J N Brady; D J Clanton; Y Ito; J Dittmer; R B Bates; R C Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

6.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.

Authors:  Jae Yeon Chun; Yan Hu; Elaine Pinder; Jianguo Wu; Fengzhi Li; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2007-09       Impact factor: 6.261

7.  Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.

Authors:  H Chen; L Teng; J N Li; R Park; D E Mold; J Gnabre; J R Hwu; W N Tseng; R C Huang
Journal:  J Med Chem       Date:  1998-07-30       Impact factor: 7.446

8.  Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.

Authors:  Santhi Konduri; Jimmie Colon; Cheryl H Baker; Stephen Safe; James L Abbruzzese; Ala Abudayyeh; Md Riyaz Basha; Maen Abdelrahim
Journal:  Mol Cancer Ther       Date:  2009-03-03       Impact factor: 6.261

9.  MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription.

Authors:  Elisa Benasciutti; Gilles Pagès; Olga Kenzior; William Folk; Francesco Blasi; Massimo P Crippa
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

10.  Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?

Authors:  Eusebio Chiefari; Antonio Brunetti; Franco Arturi; Jean-Michel Bidart; Diego Russo; Martin Schlumberger; Sebastiano Filetti
Journal:  BMC Cancer       Date:  2002-12-10       Impact factor: 4.430

View more
  28 in total

1.  Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Authors:  Mariateresa Fulciniti; Joaquin Martinez-Lopez; William Senapedis; Stefania Oliva; Rajya Lakshmi Bandi; Nicola Amodio; Yan Xu; Raphael Szalat; Annamaria Gulla; Mehmet K Samur; Aldo Roccaro; Maria Linares; Michele Cea; Erkan Baloglu; Christian Argueta; Yosef Landesman; Sharon Shacham; Siyuan Liu; Monica Schenone; Shiaw-Lin Wu; Barry Karger; Rao Prabhala; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

2.  The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Authors:  F Fan; M H Bashari; E Morelli; G Tonon; S Malvestiti; S Vallet; M Jarahian; A Seckinger; D Hose; L Bakiri; C Sun; Y Hu; C R Ball; H Glimm; M Sattler; H Goldschmidt; E F Wagner; P Tassone; D Jaeger; K Podar
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

Review 3.  MicroRNAs in multiple myeloma and related bone disease.

Authors:  Marco Rossi; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Ann Transl Med       Date:  2015-12

4.  The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.

Authors:  Jiro Kikuchi; Satoshi Yamada; Daisuke Koyama; Taeko Wada; Masaharu Nobuyoshi; Tohru Izumi; Miyuki Akutsu; Yasuhiko Kano; Yusuke Furukawa
Journal:  J Biol Chem       Date:  2013-07-22       Impact factor: 5.157

Review 5.  Targeting caspases in cancer therapeutics.

Authors:  Patrick Hensley; Murli Mishra; Natasha Kyprianou
Journal:  Biol Chem       Date:  2013-07       Impact factor: 3.915

6.  Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

Authors:  Martin F Kaiser; David C Johnson; Ping Wu; Brian A Walker; Annamaria Brioli; Fabio Mirabella; Christopher P Wardell; Lorenzo Melchor; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

7.  MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

Authors:  Mariateresa Fulciniti; Nicola Amodio; Rajya Lakshmi Bandi; Mansa Munshi; Guang Yang; Lian Xu; Zachary Hunter; Pierfrancesco Tassone; Kenneth C Anderson; Steven P Treon; Nikhil C Munshi
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

8.  Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.

Authors:  Paula M Vertino; Lawrence H Boise; Benjamin G Barwick; Vikas A Gupta; Shannon M Matulis; Jonathan C Patton; Doris R Powell; Yanyan Gu; David L Jaye; Karen N Conneely; Yin C Lin; Craig C Hofmeister; Ajay K Nooka; Jonathan J Keats; Sagar Lonial
Journal:  Clin Cancer Res       Date:  2021-03-17       Impact factor: 12.531

9.  TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.

Authors:  Jumpei Teramachi; Hirofumi Tenshin; Masahiro Hiasa; Asuka Oda; Ariunzaya Bat-Erdene; Takeshi Harada; Shingen Nakamura; Mohannad Ashtar; So Shimizu; Masami Iwasa; Kimiko Sogabe; Masahiro Oura; Shiro Fujii; Kumiko Kagawa; Hirokazu Miki; Itsuro Endo; Tatsuji Haneji; Toshio Matsumoto; Masahiro Abe
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

10.  Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors.

Authors:  Eléonore Otjacques; Marilène Binsfeld; Natacha Rocks; Silvia Blacher; Karin Vanderkerken; Agnès Noel; Yves Beguin; Didier Cataldo; Jo Caers
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.